Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

IgD-related AL amyloidosis: Clinical features and outcomes

View Full Paper
Ask AI
Bookmark
Share

Authors

TJTracy Joshi

Discussion

Loading...

Member takes

Overview

Retrospective review highlights organ involvement and prognosis in IgD-related AL amyloidosis patients, indicating potential risks and treatment responses.

Key Points

  • Median age at diagnosis was 58.3 years, and 64% of patients were male, presenting with common symptoms including dyspnea and fatigue.
  • Among 1,798 AL amyloidosis cases, 11 involved IgD monoclonal protein, with cardiac and renal involvement noted in 64% and 36% respectively.
  • Hematologic response to first-line therapy was notably high, with 86% achieving a very good partial response or better.
  • Despite a median overall survival of 9.7 years, many patients experienced disease-related complications and mortality due to IgD-related AL amyloidosis.

Cite This Study

Tracy Joshi (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e08bhttps://doi.org/10.1182/blood-2025-7500
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Presenting features, treatment patterns and predictors of outcomes in AL amyloidosis at a tertirary care cancer centre2025
  2. 2[Clinical characteristics analysis of patients with IgD type systemic light chain amyloidosis].2025
  3. 3AL amyloidosis with cardiac involvement: a case report with literature review2025
  4. 4Mortality & inpatient hospitalizations amongst patients with cardiac light-chain amyloidosis: results from a US administrative claims database2025
  5. 5Outcomes of patients with light-chain amyloidosis after heart transplantation: A single center cohort.2025